Cellectis has found a cure for bad genes. The company develops technologies involving the research and development of rational genome engineering (making changes in the genetics of a cell or organism). The company's research is primarily based on the Meganucleasus, a natural classification of DNA that isolates unique breaks at key locations within living cells. Its patented Meganuclease Recombination Systems technology helps to initiate the rational genome engineering process, which in turn can help treat diseases and augment genetic codes. In 2010 Cellectis established Cellectis Bioresearch, a US subsidiary responsible for promotion of Cellectis' products in the states.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
EMPLOYEES (This Site)
- ASSETS (MIL USD) 467
REVENUE (MIL USD)
- TICKER SYMBOL ALCLS
- Incorporated 2000
- FISCAL YEAR END DEC
- SALES GROWTH % 19.32%
Get in Touch with 12 Principals*
André CHOULIKAChairman of the Board
David SOURDIVEGeneral Manager and Board Member
Alain Paul GODARDBoard Member
Laurent ARTHAUDBoard Member